Literature DB >> 23536323

Thrombolysis of basilar artery occlusion: impact of baseline ischemia and time.

Daniel Strbian1, Tiina Sairanen, Heli Silvennoinen, Oili Salonen, Markku Kaste, Perttu J Lindsberg.   

Abstract

OBJECTIVE: To evaluate the impact of extensive baseline ischemic changes on functional outcome after thrombolysis of basilar artery occlusion (BAO), and to study the effect of time to treatment in the absence of such findings.
METHODS: We prospectively evaluated 184 consecutive patients with angiography-proven BAO. The majority of patients received intravenous alteplase and concomitant full-dose heparin. Extensive baseline ischemia was defined as posterior circulation Acute Stroke Prognosis Early CT score (pc-ASPECTS) < 8. Onset-to-treatment time (OTT) was evaluated both as a continuous and as a categorical variable (0-6 hours, 6-12 hours, 12-24 hours, and 24-48 hours). Successful recanalization means thrombolysis in myocardial infarction (TIMI) = 2 to 3. Symptomatic intracranial hemorrhage (sICH) was evaluated with National Institute of Neurological Disorders and Stroke, European Cooperative Acute Stroke Study II, and Safe Implementation of Thrombolysis in Stroke criteria. Poor 3-month outcome was defined as modified Rankin Scale score of 3 to 6.
RESULTS: The majority (96%) of patients with baseline pc-ASPECTS < 8 had poor 3-month outcome, and a similar number (94%) was observed in those of them with confirmed recanalization (51.5%). In contrast, half of the patients with pc-ASPECTS ≥ 8 and successful recanalization (73.2%) achieved good outcome. In these patients, OTT was associated with poor outcome neither as a continuous nor as a categorical variable. Factors independently associated with poor outcome were greater age and baseline National Institutes of Health Stroke Scale, lack of recanalization, history of atrial fibrillation, and sICH. In the model including the whole cohort (patients with any pc-ASPECTS), pc-ASPECTS < 8 was independently associated with poor outcome (odds ratio = 5.83, 95% confidence interval = 1.09-31.07).
INTERPRETATION: In the absence of extensive baseline ischemia, recanalization of BAO up to 48 hours was seldom futile and produced good outcomes in 50% of patients, which was independent of time to treatment.
© 2013 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23536323     DOI: 10.1002/ana.23904

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  Mechanical thrombectomy with stent retrievers in acute basilar artery occlusion.

Authors:  M Möhlenbruch; S Stampfl; L Behrens; C Herweh; S Rohde; M Bendszus; C Hametner; S Nagel; P A Ringleb; M Pham
Journal:  AJNR Am J Neuroradiol       Date:  2013-11-28       Impact factor: 3.825

2.  Patient selection for mechanical thrombectomy in posterior circulation emergent large-vessel occlusion.

Authors:  Scott Raymond; Natalia Sana Rost; Pamela Whitney Schaefer; Thabele Leslie-Mazwi; Joshua A Hirsch; Ramon Gilberto Gonzalez; James Rabinov
Journal:  Interv Neuroradiol       Date:  2017-12-12       Impact factor: 1.610

3.  Long-term outcome of endovascular therapy for acute basilar artery occlusion.

Authors:  Longfei Wu; Da Zhang; Jian Chen; Chenghe Sun; Kangxiang Ji; Weili Li; Wenbo Zhao; Chuanhui Li; Chuanjie Wu; Ming Li; Di Wu; Xunming Ji
Journal:  J Cereb Blood Flow Metab       Date:  2020-09-21       Impact factor: 6.200

Review 4.  Basilar Occlusion Syndromes: An Update.

Authors:  Stacie L Demel; Joseph P Broderick
Journal:  Neurohospitalist       Date:  2015-07

5.  Predictors for Intracranial Hemorrhage Following Intravenous Thrombolysis in Posterior Circulation Stroke.

Authors:  Tomáš Dorňák; Michal Král; Zuzana Sedláčková; Daniel Šaňák; Eva Čecháková; Petra Divišová; Jana Zapletalová; Petr Kaňovský
Journal:  Transl Stroke Res       Date:  2018-01-15       Impact factor: 6.829

6.  Assessment of Endovascular Treatment for Acute Basilar Artery Occlusion via a Nationwide Prospective Registry.

Authors:  Wenjie Zi; Zhongming Qiu; Deping Wu; Fengli Li; Hansheng Liu; Wenhua Liu; Wenguo Huang; Zhonghua Shi; Yongjie Bai; Zhensheng Liu; Li Wang; Shiquan Yang; Jie Pu; Changming Wen; Shouchun Wang; Qiyi Zhu; Wenhuo Chen; Congguo Yin; Min Lin; Li Qi; Yaoyi Zhong; Zhen Wang; Wenjun Wu; Huisheng Chen; Xiaoxi Yao; Feng Xiong; Guoyong Zeng; Zhiming Zhou; Zhilin Wu; Yue Wan; Huiyuan Peng; Bing Li; Xinping Hu; Hongbin Wen; Wangtao Zhong; Leyuan Wang; Ping Jin; Fuqiang Guo; Ju Han; Xinmin Fu; Zhibing Ai; Xiguang Tian; Xiaoya Feng; Bo Sun; Zhizhi Huang; Wei Li; Peiyang Zhou; Mingyi Tu; Xiangrong Sun; Hua Li; Wencheng He; Tao Qiu; Zhengzhou Yuan; Chengsong Yue; Jun Yang; Weidong Luo; Zili Gong; Jie Shuai; Raul Gomes Nogueira; Qingwu Yang
Journal:  JAMA Neurol       Date:  2020-05-01       Impact factor: 18.302

7.  Prolonged low-dose thrombolysis in posterior circulation stroke.

Authors:  C Hametner; L Kellert; R Veltkamp; L Behrens; S Nagel; W Hacke; P Ringleb
Journal:  Neurocrit Care       Date:  2014-08       Impact factor: 3.210

8.  Recanalization treatments in basilar artery occlusion-Systematic analysis.

Authors:  Perttu J Lindsberg; Tiina Sairanen; Simon Nagel; Oili Salonen; Heli Silvennoinen; Daniel Strbian
Journal:  Eur Stroke J       Date:  2016-03-01

9.  Posterior Circulation Endovascular Thrombectomy for Large-Vessel Occlusion: Predictors of Favorable Clinical Outcome and Analysis of First-Pass Effect.

Authors:  A M Alexandre; I Valente; A Consoli; M Piano; L Renieri; J D Gabrieli; R Russo; A A Caragliano; M Ruggiero; A Saletti; G A Lazzarotti; M Pileggi; N Limbucci; M Cosottini; A Cervo; F Viaro; S L Vinci; C Commodaro; F Pilato; A Pedicelli
Journal:  AJNR Am J Neuroradiol       Date:  2021-03-04       Impact factor: 3.825

10.  Prognostic Structural Neural Markers of MRI in Response to Mechanical Thrombectomy for Basilar Artery Occlusion.

Authors:  Chang Liu; Jia-Xin Song; Zhang-Bao Guo; Lu-Ming Chen; Chen-Hao Zhao; Wen-Jie Zi; Qing-Wu Yang
Journal:  Front Neurol       Date:  2021-06-09       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.